ARS Pharmaceuticals Inc. (SPRY) announced that China's NMPA has approved neffy, the first and only needle-free epinephrine nasal spray, for the emergency treatment of Type I allergic reactions in adults and children weighing 30 kg or more.
Pediatrix Therapeutics, which has a license from ARS Pharma to market neffy in China, expects the product to be available in the spring of 2026.
Neffy is already approved in the United States, European Union, United Kingdom, Japan and Australia, where it serves as a needle-free alternative to epinephrine auto-injectors.
For the third quarter of 2025, neffy generated $31.3 million in net product revenue compared to $0.57 million in the year-ago quarter.
The company noted that the neffy's simple, needle-free design may helo reduce delays in epinephrine administration, a major barrier in managing severe allergic reactions. With China representing a large population at risk for anaphylaxis and lacking community-use epinephrine products, the approval significantly expands neffy's global market opportunity.
SPRY has traded between $6.66 and $18.90 over the past year. The stock is currently trading at $11.45, up 0.62%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.